Board Members

Jerry R. Youkey, M.D.

Jerry Youkey

Jerry R. Youkey, M.D., joined Greenville Health System (GHS) in 1998, and currently serves as GHS Executive Vice President and Chief Academic Officer, reporting to the CEO. GHS is an eight-campus integrated delivery system with 1,756 beds, employing approximately 14,000 employees and 1,000 medical doctors.  Since 2011, Dr. Youkey has additionally served as Founding Dean of University of South Carolina School of Medicine Greenville and in 2015, was appointed University of South Carolina Associate provost for Health Sciences Greenville.

Dr. Youkey served a rotating internship and general surgery residency at William Beaumont Army Medical Center, El Paso, TX, and a fellowship in peripheral vascular surgery at Walter Reed Army Medical Center, Washington D.C. He also served in the U.S. Army and was honorably discharged in August 1984, after attaining the rank of Colonel, Medical Corps. Dr. Youkey served as Chief, Department of Surgery and Director, Peripheral Vascular Surgery Fellowship Program at Geisinger Medical Center, Danville, PA, prior to coming to Greenville. He is certified by the American Board of Surgery in general vascular surgery.

He is widely published in his specialty field of general vascular surgery, having authored books, abstracts and journal articles. He holds the academic appointment of Professor and Associate Dean at the University of South Carolina, Columbia, SC. He received his B.A. from Stanford University, Palo Alto, CA, his medical degree from the Medical College of Wisconsin, Milwaukee, WI and is a member of numerous professional societies and organizations.

Dale Zajicek, Board Member

Dale Zajicek

Mr. Zajicek has over 37 years of experience in the pharmaceutical and biotech industry. In 2015 he retired as President of BioVectra, Inc., located in Charlottetown, Prince Edward Island, Canada, and was with this company since 1995. Following his promotion to Chief Operating Officer in 2005, he has been responsible for significant growth of the firm’s contract manufacturing and drug development efforts, with the firm filing numerous Drug Master Files (DMF), Investigational New Drug applications (IND), and supported the New Drug Applications for numerous clients.

Mr. Zajicek successfully led BioVectra to the development of generic docetaxel, and obtained first to file status for this $1 billion annual sales oncology drug. BioVectra successfully partnered the product with Sandoz for the US market, and other marketing firms for markets in Canada, Europe, Middle East, North Africa, and South America. BioVectra is engaged with clients and partners on several clinical phase, pre-commercial, and commercial opportunities. Under Mr. Zajicek’s leadership, BioVectra has developed capabilities in microbial fermentation for protein-based and small molecule drugs, as well as combining biotech processing with synthetic capabilities to perform unique chemistries and conjugations of large to small molecules.

Prior to joining BioVectra, Mr. Zajicek held positions in manufacturing operations, engineering, research and product development, and business development at G. D. Searle and The NutraSweet Company.

He holds a BS in Chemical Engineering from Illinois Institute of Technology and a BS in Business Administration from Elmhurst College. He has an in-depth working knowledge of the process development and commercial processing.

Sherry Grisewood, Board Member

Ms. Grisewood has been active at the Board level for several early stage life science and medical device companies over the last 20 years. She is currently the Audit Committee Chair and is a member of the Compensation Committee for TapImmune, Inc., a NASDAQ-listed, clinical stage cancer immunotherapy company and is a member of the Board of Directors of Mobitech Regenerative Medicine, Inc., an early stage orthopedics device company.

Previously, she served as Managing Partner of Life Sciences Research and prior to that posting, Managing Director of Corporate Finance, at Dawson James Securities, Inc., Research Division and Managing Director, Lifesciences and Technology Banking for Tripoint Global Equities. She has also performed as Senior Life Sciences Banker at Jesup & Lamont Securities Corp. and as an independent strategic advisor and consultant for several investment banks and was Director of Research for several mid-tier brokerage companies and a leading independent investment research company.

She holds a Bachelor of Science degree, with Highest Honors, in Life Sciences from Ramapo College of New Jersey, the Chartered Financial Analyst (CFA) designation and is a member of CFA Institute, the American Society of Gene & Cell Therapy and the Tissue Engineering & Regenerative Medicine Intl. Society.

John Holaday, PhD

Dr. Holaday has a track record of accomplishments as a senior executive at several growing biopharmaceutical companies. Most recently, until his retirement in 2014, Dr. Holaday was co-founder, chief executive officer, managing director and board member of QRxPharma, a specialty pharmaceutical company headquartered in Sydney, Australia, where he directed the development and NDA submission of a better-tolerated opioid.

Prior to founding QRx in 2007, he was co-founder of the technology-focused Harvest Bank of Maryland and co-founder and chief executive officer of EntreMed, Inc., a pioneering anti-angiogenesis company focused on oncology. He co-founded MaxCyte, a flow electroporation company. Prior to that, he was co-founder and executive vice president of Research and Development at Medicis Pharmaceutical Corp., a dermatology company acquired by Valeant Pharmaceuticals in 2012 for $2.6B.

He is currently a board member for several biopharmaceutical companies and non-profit organizations. He earned his B.S. and M.S. from the University of Alabama, and his Ph.D. in Pharmacology from the University of California, San Francisco School of Medicine. He holds over 90 patents and has published over 230 scientific articles, book chapters and four books. He served as Chair of the BioAlliance of the Tech Council of Maryland. In 2006, he was named to the Ernst & Young’s Entrepreneur of the Year Hall of Fame.